Dalmelitinib [CAS 1637658-98-0]

Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) [1].

[1637658-98-0]

C22H16FN7O2S

461.47

O=C1N(C)C2=CN=C3C=CC(SC4=NN=C5C(F)=CC(C6=CN(C)N=C6)=CN45)=CC3=C2OC1

C-Met/HGFR

98.28

DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature